Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-11-16

AUTHORS

Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda, Koichi Node

ABSTRACT

BackgroundAnagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain.Aim and methodsWe therefore evaluate the effects of anagliptin on lipid metabolism-related markers compared with those of sitagliptin. The study was a secondary analysis using data obtained from the Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. This trial in patients with type 2 diabetes at a high risk of cardiovascular events and on statin therapy showed that anagliptin reduced LDL-C levels to a greater extent than sitagliptin. Cholesterol absorption (campesterol and sitosterol) and synthesis (lathosterol) markers were measured at baseline and 52 weeks in the study cohort (n = 353).ResultsThere was no significant difference in the changes of campesterol or sitosterol between the two treatment groups (p = 0.85 and 0.55, respectively). Lathosterol concentration was increased significantly at 52 weeks with sitagliptin treatment (baseline, 1.2 ± 0.7 μg/mL vs. 52 weeks, 1.4 ± 1.0 μg/mL, p = 0.02), whereas it did not change in the anagliptin group (baseline, 1.3 ± 0.8 μg/mL vs. 52 weeks, 1.3 ± 0.7 μg/mL, p = 0.99). The difference in absolute change between the two groups showed a borderline significance (p = 0.06).ConclusionThese findings suggest that anagliptin reduces LDL-C level by suppressing excess cholesterol synthesis, even in combination with statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. https://clinicaltrials.gov/ct2/show/NCT02330406; registered January 5, 2015. More... »

PAGES

158

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3

DOI

http://dx.doi.org/10.1186/s12933-019-0965-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1122658455

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31733647


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dipeptidyl-Peptidase IV Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dyslipidemias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phytosterols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sitagliptin Phosphate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sitosterols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412339.e", 
          "name": [
            "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chihara", 
        "givenName": "Atsuko", 
        "id": "sg:person.013676443224.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013676443224.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412339.e", 
          "name": [
            "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Atsushi", 
        "id": "sg:person.012413241515.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012413241515.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Takeshi", 
        "id": "sg:person.011273662612.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakuma", 
        "givenName": "Mio", 
        "id": "sg:person.01041233531.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041233531.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411582.b", 
          "name": [
            "Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimabukuro", 
        "givenName": "Michio", 
        "id": "sg:person.01233731752.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233731752.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nomiyama", 
        "givenName": "Takashi", 
        "id": "sg:person.01255040512.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255040512.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan", 
          "id": "http://www.grid.ac/institutes/grid.460111.3", 
          "name": [
            "Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arasaki", 
        "givenName": "Osamu", 
        "id": "sg:person.0611455170.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611455170.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.267625.2", 
          "name": [
            "Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueda", 
        "givenName": "Shinichiro", 
        "id": "sg:person.012353001702.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012353001702.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412339.e", 
          "name": [
            "Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Node", 
        "givenName": "Koichi", 
        "id": "sg:person.01100453460.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100453460.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12020-014-0376-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022989679", 
          "https://doi.org/10.1007/s12020-014-0376-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-011-0088-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005706723", 
          "https://doi.org/10.1007/s12325-011-0088-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10557-018-6776-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100981423", 
          "https://doi.org/10.1007/s10557-018-6776-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-019-44885-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117069698", 
          "https://doi.org/10.1038/s41598-019-44885-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-017-0607-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092156137", 
          "https://doi.org/10.1186/s12933-017-0607-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-11-16", 
    "datePublishedReg": "2019-11-16", 
    "description": "BackgroundAnagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain.Aim and methodsWe therefore evaluate the effects of anagliptin on lipid metabolism-related markers compared with those of sitagliptin. The study was a secondary analysis using data obtained from the Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. This trial in patients with type 2 diabetes at a high risk of cardiovascular events and on statin therapy showed that anagliptin reduced LDL-C levels to a greater extent than sitagliptin. Cholesterol absorption (campesterol and sitosterol) and synthesis (lathosterol) markers were measured at baseline and 52\u00a0weeks in the study cohort (n\u2009=\u2009353).ResultsThere was no significant difference in the changes of campesterol or sitosterol between the two treatment groups (p\u2009=\u20090.85 and 0.55, respectively). Lathosterol concentration was increased significantly at 52\u00a0weeks with sitagliptin treatment (baseline, 1.2\u2009\u00b1\u20090.7\u00a0\u03bcg/mL vs. 52\u00a0weeks, 1.4\u2009\u00b1\u20091.0\u00a0\u03bcg/mL, p\u2009=\u20090.02), whereas it did not change in the anagliptin group (baseline, 1.3\u2009\u00b1\u20090.8\u00a0\u03bcg/mL vs. 52\u00a0weeks, 1.3\u2009\u00b1\u20090.7\u00a0\u03bcg/mL, p\u2009=\u20090.99). The difference in absolute change between the two groups showed a borderline significance (p\u2009=\u20090.06).ConclusionThese findings suggest that anagliptin reduces LDL-C level by suppressing excess cholesterol synthesis, even in combination with statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. https://clinicaltrials.gov/ct2/show/NCT02330406; registered January 5, 2015.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12933-019-0965-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1031021", 
        "issn": [
          "1475-2840"
        ], 
        "name": "Cardiovascular Diabetology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "low-density lipoprotein cholesterol", 
      "LDL-C levels", 
      "type 2 diabetes", 
      "statin therapy", 
      "lipoprotein cholesterol", 
      "secondary analysis", 
      "lipid metabolism", 
      "dipeptidyl peptidase-4 inhibitors", 
      "peptidase-4 inhibitors", 
      "effects of anagliptin", 
      "metabolism-related markers", 
      "anagliptin group", 
      "REASON trial", 
      "cardiovascular events", 
      "Diabetes (ACCORD) trial", 
      "sitagliptin treatment", 
      "study cohort", 
      "borderline significance", 
      "cholesterol absorption", 
      "high risk", 
      "treatment groups", 
      "lathosterol concentration", 
      "synthesis markers", 
      "ConclusionThese findings", 
      "anagliptin", 
      "Randomized Evaluation", 
      "sitagliptin", 
      "cholesterol synthesis", 
      "therapy", 
      "absolute change", 
      "trials", 
      "significant differences", 
      "underlying mechanism", 
      "patients", 
      "diabetes", 
      "cholesterol", 
      "weeks", 
      "markers", 
      "metabolism", 
      "group", 
      "ResultsThere", 
      "cohort", 
      "levels", 
      "MethodsWe", 
      "differences", 
      "baseline", 
      "greater extent", 
      "treatment", 
      "risk", 
      "inhibitors", 
      "effect", 
      "changes", 
      "findings", 
      "evaluation", 
      "significance", 
      "study", 
      "campesterol", 
      "sitosterol", 
      "events", 
      "analysis", 
      "concentration", 
      "mechanism", 
      "combination", 
      "extent", 
      "data", 
      "absorption", 
      "synthesis"
    ], 
    "name": "Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial", 
    "pagination": "158", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1122658455"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12933-019-0965-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31733647"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12933-019-0965-3", 
      "https://app.dimensions.ai/details/publication/pub.1122658455"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_830.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12933-019-0965-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12933-019-0965-3'


 

This table displays all metadata directly associated to this object as RDF triples.

294 TRIPLES      21 PREDICATES      116 URIs      103 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12933-019-0965-3 schema:about N1a8b350f7b09489daecaab168c0699bd
2 N2416d32838e74acb897044237ea83021
3 N450320857aca4a12998bc67afe3fc3a1
4 N45c0c7873eee4b2c9b0e7b14c6047c30
5 N51cc5f5f758947089ae762bb9dc01d59
6 N5945997f7169470386b1ddd4c5e70a56
7 N656168f26adb465ead60546a8d2c544d
8 N70e8dda6c73b4804a69a37988896be0c
9 N72b0f39dff68423f90cb50ab63ed70e1
10 N81d2f4c75ffb492ba40b2e70c34721eb
11 N86b722d62cb44e4c993a1f1ac8d7a1bf
12 N9558cd866cb24e9491ef925927194bd4
13 Na2eebe4f8666435e8bb0400cfded3096
14 Nbf38ba9a1e154ba8bee467c34f7498c8
15 Nc6c6a3712e93449cb4478e39849293ca
16 Nc77c08cbfd7347269051a3e642344201
17 Nd9c28572cfc2438cbbc03d390d334435
18 Nf196527737384fbd9cb475dc4c17decd
19 Nf69e70b5b13d4b47bd63e4c290c1bd42
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N78cd96e9af444ba1ba755b0118efa819
23 schema:citation sg:pub.10.1007/s10557-018-6776-z
24 sg:pub.10.1007/s12020-014-0376-x
25 sg:pub.10.1007/s12325-011-0088-z
26 sg:pub.10.1038/s41598-019-44885-x
27 sg:pub.10.1186/s12933-017-0607-6
28 schema:datePublished 2019-11-16
29 schema:datePublishedReg 2019-11-16
30 schema:description BackgroundAnagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain.Aim and methodsWe therefore evaluate the effects of anagliptin on lipid metabolism-related markers compared with those of sitagliptin. The study was a secondary analysis using data obtained from the Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. This trial in patients with type 2 diabetes at a high risk of cardiovascular events and on statin therapy showed that anagliptin reduced LDL-C levels to a greater extent than sitagliptin. Cholesterol absorption (campesterol and sitosterol) and synthesis (lathosterol) markers were measured at baseline and 52 weeks in the study cohort (n = 353).ResultsThere was no significant difference in the changes of campesterol or sitosterol between the two treatment groups (p = 0.85 and 0.55, respectively). Lathosterol concentration was increased significantly at 52 weeks with sitagliptin treatment (baseline, 1.2 ± 0.7 μg/mL vs. 52 weeks, 1.4 ± 1.0 μg/mL, p = 0.02), whereas it did not change in the anagliptin group (baseline, 1.3 ± 0.8 μg/mL vs. 52 weeks, 1.3 ± 0.7 μg/mL, p = 0.99). The difference in absolute change between the two groups showed a borderline significance (p = 0.06).ConclusionThese findings suggest that anagliptin reduces LDL-C level by suppressing excess cholesterol synthesis, even in combination with statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. https://clinicaltrials.gov/ct2/show/NCT02330406; registered January 5, 2015.
31 schema:genre article
32 schema:isAccessibleForFree true
33 schema:isPartOf N3b5416829a2446f193f84be1903c13dc
34 Nfce8a3df8e6b4e67a38422a251be3346
35 sg:journal.1031021
36 schema:keywords ConclusionThese findings
37 Diabetes (ACCORD) trial
38 LDL-C levels
39 MethodsWe
40 REASON trial
41 Randomized Evaluation
42 ResultsThere
43 absolute change
44 absorption
45 anagliptin
46 anagliptin group
47 analysis
48 baseline
49 borderline significance
50 campesterol
51 cardiovascular events
52 changes
53 cholesterol
54 cholesterol absorption
55 cholesterol synthesis
56 cohort
57 combination
58 concentration
59 data
60 diabetes
61 differences
62 dipeptidyl peptidase-4 inhibitors
63 effect
64 effects of anagliptin
65 evaluation
66 events
67 extent
68 findings
69 greater extent
70 group
71 high risk
72 inhibitors
73 lathosterol concentration
74 levels
75 lipid metabolism
76 lipoprotein cholesterol
77 low-density lipoprotein cholesterol
78 markers
79 mechanism
80 metabolism
81 metabolism-related markers
82 patients
83 peptidase-4 inhibitors
84 risk
85 secondary analysis
86 significance
87 significant differences
88 sitagliptin
89 sitagliptin treatment
90 sitosterol
91 statin therapy
92 study
93 study cohort
94 synthesis
95 synthesis markers
96 therapy
97 treatment
98 treatment groups
99 trials
100 type 2 diabetes
101 underlying mechanism
102 weeks
103 schema:name Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
104 schema:pagination 158
105 schema:productId N173f82ef34224e08b7b7520517424bfa
106 N6b53aaf3214045cca1e602c9ae2f2f0f
107 N85951013f48d4a95b90efdc14df6d772
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122658455
109 https://doi.org/10.1186/s12933-019-0965-3
110 schema:sdDatePublished 2022-10-01T06:46
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher Nc94f418c77d6432ab4c2b66df530c07d
113 schema:url https://doi.org/10.1186/s12933-019-0965-3
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N0863675511cc45578a8d0cca0a223770 rdf:first sg:person.0611455170.93
118 rdf:rest Na09c7652cfd4415c8c626597166f0ed3
119 N13008f20f960468eb991e4a382d8e392 rdf:first sg:person.011273662612.03
120 rdf:rest N2da26139921944a99141590d5b5b4182
121 N173f82ef34224e08b7b7520517424bfa schema:name dimensions_id
122 schema:value pub.1122658455
123 rdf:type schema:PropertyValue
124 N1a8b350f7b09489daecaab168c0699bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Aged
126 rdf:type schema:DefinedTerm
127 N2416d32838e74acb897044237ea83021 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Biomarkers
129 rdf:type schema:DefinedTerm
130 N2da26139921944a99141590d5b5b4182 rdf:first sg:person.01041233531.06
131 rdf:rest Nde9eea7c7b1641e98fe74038489e723f
132 N3b5416829a2446f193f84be1903c13dc schema:issueNumber 1
133 rdf:type schema:PublicationIssue
134 N450320857aca4a12998bc67afe3fc3a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Cholesterol, LDL
136 rdf:type schema:DefinedTerm
137 N45c0c7873eee4b2c9b0e7b14c6047c30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Dyslipidemias
139 rdf:type schema:DefinedTerm
140 N4627ef52d86a4c4d92bc2720c25b0d22 rdf:first sg:person.01255040512.80
141 rdf:rest N0863675511cc45578a8d0cca0a223770
142 N464f7fb9580c4e35adf7e5d5c40869f0 rdf:first sg:person.012413241515.35
143 rdf:rest N13008f20f960468eb991e4a382d8e392
144 N51cc5f5f758947089ae762bb9dc01d59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Male
146 rdf:type schema:DefinedTerm
147 N5945997f7169470386b1ddd4c5e70a56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Japan
149 rdf:type schema:DefinedTerm
150 N656168f26adb465ead60546a8d2c544d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Diabetes Mellitus, Type 2
152 rdf:type schema:DefinedTerm
153 N6b53aaf3214045cca1e602c9ae2f2f0f schema:name pubmed_id
154 schema:value 31733647
155 rdf:type schema:PropertyValue
156 N70e8dda6c73b4804a69a37988896be0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Middle Aged
158 rdf:type schema:DefinedTerm
159 N728cf85b8bee45c6b1cde0fc89cb2aa6 rdf:first sg:person.01100453460.13
160 rdf:rest rdf:nil
161 N72b0f39dff68423f90cb50ab63ed70e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Dipeptidyl-Peptidase IV Inhibitors
163 rdf:type schema:DefinedTerm
164 N78cd96e9af444ba1ba755b0118efa819 rdf:first sg:person.013676443224.16
165 rdf:rest N464f7fb9580c4e35adf7e5d5c40869f0
166 N81d2f4c75ffb492ba40b2e70c34721eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Female
168 rdf:type schema:DefinedTerm
169 N85951013f48d4a95b90efdc14df6d772 schema:name doi
170 schema:value 10.1186/s12933-019-0965-3
171 rdf:type schema:PropertyValue
172 N86b722d62cb44e4c993a1f1ac8d7a1bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Sitagliptin Phosphate
174 rdf:type schema:DefinedTerm
175 N9558cd866cb24e9491ef925927194bd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Time Factors
177 rdf:type schema:DefinedTerm
178 Na09c7652cfd4415c8c626597166f0ed3 rdf:first sg:person.012353001702.96
179 rdf:rest N728cf85b8bee45c6b1cde0fc89cb2aa6
180 Na2eebe4f8666435e8bb0400cfded3096 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Phytosterols
182 rdf:type schema:DefinedTerm
183 Nbf38ba9a1e154ba8bee467c34f7498c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Cholesterol
185 rdf:type schema:DefinedTerm
186 Nc6c6a3712e93449cb4478e39849293ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Sitosterols
188 rdf:type schema:DefinedTerm
189 Nc77c08cbfd7347269051a3e642344201 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
191 rdf:type schema:DefinedTerm
192 Nc94f418c77d6432ab4c2b66df530c07d schema:name Springer Nature - SN SciGraph project
193 rdf:type schema:Organization
194 Nd9c28572cfc2438cbbc03d390d334435 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Pyrimidines
196 rdf:type schema:DefinedTerm
197 Nde9eea7c7b1641e98fe74038489e723f rdf:first sg:person.01233731752.49
198 rdf:rest N4627ef52d86a4c4d92bc2720c25b0d22
199 Nf196527737384fbd9cb475dc4c17decd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Treatment Outcome
201 rdf:type schema:DefinedTerm
202 Nf69e70b5b13d4b47bd63e4c290c1bd42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Humans
204 rdf:type schema:DefinedTerm
205 Nfce8a3df8e6b4e67a38422a251be3346 schema:volumeNumber 18
206 rdf:type schema:PublicationVolume
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
211 schema:name Clinical Sciences
212 rdf:type schema:DefinedTerm
213 sg:journal.1031021 schema:issn 1475-2840
214 schema:name Cardiovascular Diabetology
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.01041233531.06 schema:affiliation grid-institutes:grid.272264.7
218 schema:familyName Sakuma
219 schema:givenName Mio
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041233531.06
221 rdf:type schema:Person
222 sg:person.01100453460.13 schema:affiliation grid-institutes:grid.412339.e
223 schema:familyName Node
224 schema:givenName Koichi
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100453460.13
226 rdf:type schema:Person
227 sg:person.011273662612.03 schema:affiliation grid-institutes:grid.272264.7
228 schema:familyName Morimoto
229 schema:givenName Takeshi
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03
231 rdf:type schema:Person
232 sg:person.01233731752.49 schema:affiliation grid-institutes:grid.411582.b
233 schema:familyName Shimabukuro
234 schema:givenName Michio
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233731752.49
236 rdf:type schema:Person
237 sg:person.012353001702.96 schema:affiliation grid-institutes:grid.267625.2
238 schema:familyName Ueda
239 schema:givenName Shinichiro
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012353001702.96
241 rdf:type schema:Person
242 sg:person.012413241515.35 schema:affiliation grid-institutes:grid.412339.e
243 schema:familyName Tanaka
244 schema:givenName Atsushi
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012413241515.35
246 rdf:type schema:Person
247 sg:person.01255040512.80 schema:affiliation grid-institutes:grid.411497.e
248 schema:familyName Nomiyama
249 schema:givenName Takashi
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255040512.80
251 rdf:type schema:Person
252 sg:person.013676443224.16 schema:affiliation grid-institutes:grid.412339.e
253 schema:familyName Chihara
254 schema:givenName Atsuko
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013676443224.16
256 rdf:type schema:Person
257 sg:person.0611455170.93 schema:affiliation grid-institutes:grid.460111.3
258 schema:familyName Arasaki
259 schema:givenName Osamu
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611455170.93
261 rdf:type schema:Person
262 sg:pub.10.1007/s10557-018-6776-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1100981423
263 https://doi.org/10.1007/s10557-018-6776-z
264 rdf:type schema:CreativeWork
265 sg:pub.10.1007/s12020-014-0376-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1022989679
266 https://doi.org/10.1007/s12020-014-0376-x
267 rdf:type schema:CreativeWork
268 sg:pub.10.1007/s12325-011-0088-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1005706723
269 https://doi.org/10.1007/s12325-011-0088-z
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/s41598-019-44885-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1117069698
272 https://doi.org/10.1038/s41598-019-44885-x
273 rdf:type schema:CreativeWork
274 sg:pub.10.1186/s12933-017-0607-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092156137
275 https://doi.org/10.1186/s12933-017-0607-6
276 rdf:type schema:CreativeWork
277 grid-institutes:grid.267625.2 schema:alternateName Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan
278 schema:name Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan
279 rdf:type schema:Organization
280 grid-institutes:grid.272264.7 schema:alternateName Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
281 schema:name Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
282 rdf:type schema:Organization
283 grid-institutes:grid.411497.e schema:alternateName Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan
284 schema:name Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan
285 rdf:type schema:Organization
286 grid-institutes:grid.411582.b schema:alternateName Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan
287 schema:name Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan
288 rdf:type schema:Organization
289 grid-institutes:grid.412339.e schema:alternateName Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan
290 schema:name Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, 849-8501, Saga, Japan
291 rdf:type schema:Organization
292 grid-institutes:grid.460111.3 schema:alternateName Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan
293 schema:name Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan
294 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...